Visioneering Technologies Inc said today it closed a $25.5 million (AUD $33.3 million) initial public offering in Australia, with funds slated to support its NaturalVue multifocal contact lenses.
In the offering, the Alpharetta, Ga.-based company floated approximately 79.4 million shares of Class A common stock at 32¢ (AUD 42¢) per share, with strong support from Australian and Asian investors. The IPO was fully underwritten by Cannacord Genuity.
“With a very successful pilot launch completed, with the calibre of sales leadership we have recently attracted and installed, and with a successful IPO enabling rapid expansion of our sales infrastructure, new product launches, and inventory, we are well poised to deliver on the growth plans laid out in our prospectus,” CEO Dr. Stephen Snowdy said in a press release.
Visioneering Technologies said it won FDA clearance in the US, and that proceeds will support a broadened launch of its NaturalView MF daily disposable contact lenses both adults with presbyopia and children with myopia.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.